Avricore Health Inc. (AVCR.V)
CAD 0.05
(0.0%)
CAD 0.05
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -275.13 Thousand CAD | 56.64% |
| 2022 | -629.75 Thousand CAD | 63.71% |
| 2021 | -1.64 Million CAD | -101.01% |
| 2020 | -930.39 Thousand CAD | 39.5% |
| 2019 | -1.72 Million CAD | 39.48% |
| 2018 | -2.92 Million CAD | -18.92% |
| 2017 | -2.75 Million CAD | 3.05% |
| 2016 | -2.59 Million CAD | 12.94% |
| 2015 | -2.33 Million CAD | -36.44% |
| 2014 | -1.71 Million CAD | -122.43% |
| 2013 | -773.68 Thousand CAD | -300.06% |
| 2012 | -192.54 Thousand CAD | 49.89% |
| 2011 | -291.87 Thousand CAD | 79.41% |
| 2010 | -1.86 Million CAD | 54.0% |
| 2009 | -3.99 Million CAD | -223.13% |
| 2008 | -1.25 Million CAD | 34.8% |
| 2007 | -1.92 Million CAD | -246.01% |
| 2006 | -545.8 Thousand CAD | -24.6% |
| 2005 | -368.45 Thousand CAD | -48.93% |
| 2004 | -544.81 Thousand CAD | 15.47% |
| 2003 | -543.68 Thousand CAD | -572.56% |
| 2002 | -52.73 Thousand CAD | 23.5% |
| 2001 | -68.93 Thousand CAD | -449.26% |
| 2000 | -12.55 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 424.8 Thousand CAD | -39.13% |
| 2024 Q1 | 274.34 Thousand CAD | 41.94% |
| 2023 FY | - CAD | 56.64% |
| 2023 Q2 | -281.4 Thousand CAD | -147.0% |
| 2023 Q3 | -161.58 Thousand CAD | 42.58% |
| 2023 Q4 | 197.77 Thousand CAD | 222.4% |
| 2023 Q1 | -113.93 Thousand CAD | 28.44% |
| 2022 Q1 | -177.99 Thousand CAD | 36.18% |
| 2022 Q2 | -185.29 Thousand CAD | -4.1% |
| 2022 Q3 | -104.3 Thousand CAD | 43.71% |
| 2022 Q4 | -159.21 Thousand CAD | -52.65% |
| 2022 FY | - CAD | 63.71% |
| 2021 Q3 | -429.75 Thousand CAD | -26.02% |
| 2021 FY | - CAD | -101.01% |
| 2021 Q1 | -677.32 Thousand CAD | -113.64% |
| 2021 Q2 | -341.02 Thousand CAD | 49.65% |
| 2021 Q4 | -278.92 Thousand CAD | 35.1% |
| 2020 FY | - CAD | 39.5% |
| 2020 Q2 | -170.34 Thousand CAD | 17.63% |
| 2020 Q1 | -206.8 Thousand CAD | -28.74% |
| 2020 Q4 | -317.03 Thousand CAD | -91.9% |
| 2020 Q3 | -165.2 Thousand CAD | 3.02% |
| 2019 Q1 | -521.3 Thousand CAD | 13.07% |
| 2019 FY | - CAD | 39.48% |
| 2019 Q4 | -160.64 Thousand CAD | 56.03% |
| 2019 Q3 | -365.35 Thousand CAD | 2.06% |
| 2019 Q2 | -373.04 Thousand CAD | 28.44% |
| 2018 FY | - CAD | -18.92% |
| 2018 Q4 | -599.71 Thousand CAD | 2.45% |
| 2018 Q3 | -614.77 Thousand CAD | -7.39% |
| 2018 Q2 | -572.46 Thousand CAD | -2.34% |
| 2018 Q1 | -559.38 Thousand CAD | 16.98% |
| 2017 Q2 | -371.17 Thousand CAD | -602.44% |
| 2017 FY | - CAD | 3.05% |
| 2017 Q4 | -673.76 Thousand CAD | -23.89% |
| 2017 Q3 | -543.84 Thousand CAD | -46.52% |
| 2017 Q1 | -52.84 Thousand CAD | 91.42% |
| 2016 FY | - CAD | 12.94% |
| 2016 Q1 | -711.85 Thousand CAD | -11.66% |
| 2016 Q3 | -310.44 Thousand CAD | 22.38% |
| 2016 Q2 | -399.96 Thousand CAD | 43.81% |
| 2016 Q4 | -615.94 Thousand CAD | -98.41% |
| 2015 Q4 | -637.51 Thousand CAD | -13.33% |
| 2015 Q1 | -455.87 Thousand CAD | -11.42% |
| 2015 Q2 | -218.15 Thousand CAD | 52.15% |
| 2015 Q3 | -562.54 Thousand CAD | -157.87% |
| 2015 FY | - CAD | -36.44% |
| 2014 Q2 | -257.03 Thousand CAD | -10.25% |
| 2014 FY | - CAD | -122.43% |
| 2014 Q3 | -156.63 Thousand CAD | 39.06% |
| 2014 Q4 | -409.14 Thousand CAD | -161.21% |
| 2014 Q1 | -233.12 Thousand CAD | -113.18% |
| 2013 FY | - CAD | -300.06% |
| 2013 Q4 | -109.35 Thousand CAD | 35.3% |
| 2013 Q3 | -169.03 Thousand CAD | -70.09% |
| 2013 Q1 | -34.88 Thousand CAD | -15.3% |
| 2013 Q2 | -99.38 Thousand CAD | -184.91% |
| 2012 Q4 | -30.25 Thousand CAD | -16.72% |
| 2012 FY | - CAD | 49.89% |
| 2012 Q1 | -55.33 Thousand CAD | 7.49% |
| 2012 Q2 | -86.31 Thousand CAD | -55.98% |
| 2012 Q3 | -25.91 Thousand CAD | 69.97% |
| 2011 Q3 | -179.37 Thousand CAD | 81.07% |
| 2011 FY | - CAD | 79.41% |
| 2011 Q1 | -261.46 Thousand CAD | 73.46% |
| 2011 Q2 | -947.69 Thousand CAD | -262.46% |
| 2011 Q4 | -59.81 Thousand CAD | 66.65% |
| 2010 FY | - CAD | 54.0% |
| 2010 Q1 | -1.73 Million CAD | -407.6% |
| 2010 Q2 | -1.28 Million CAD | 25.84% |
| 2010 Q4 | -985.01 Thousand CAD | -195.62% |
| 2010 Q3 | -333.2 Thousand CAD | 74.12% |
| 2009 FY | - CAD | -223.13% |
| 2009 Q4 | -341.97 Thousand CAD | 50.5% |
| 2009 Q3 | -690.81 Thousand CAD | -55.69% |
| 2009 Q2 | -443.71 Thousand CAD | -87.16% |
| 2009 Q1 | -237.07 Thousand CAD | 23.12% |
| 2008 Q4 | -308.35 Thousand CAD | -17.08% |
| 2008 Q1 | -328.95 Thousand CAD | 42.55% |
| 2008 Q2 | -889.86 Thousand CAD | -170.52% |
| 2008 Q3 | -263.38 Thousand CAD | 70.4% |
| 2008 FY | - CAD | 34.8% |
| 2007 Q1 | -85.87 Thousand CAD | 2.54% |
| 2007 Q2 | -258.08 Thousand CAD | -200.53% |
| 2007 FY | - CAD | -246.01% |
| 2007 Q4 | -572.62 Thousand CAD | -328.57% |
| 2007 Q3 | -133.61 Thousand CAD | 48.23% |
| 2006 Q4 | -88.11 Thousand CAD | 29.11% |
| 2006 FY | - CAD | -24.6% |
| 2006 Q2 | -65.31 Thousand CAD | 43.87% |
| 2006 Q1 | -116.35 Thousand CAD | 14.64% |
| 2006 Q3 | -124.28 Thousand CAD | -90.3% |
| 2005 Q4 | -136.3 Thousand CAD | -6.04% |
| 2005 Q3 | -128.54 Thousand CAD | -3.49% |
| 2005 Q1 | -132.97 Thousand CAD | 10.26% |
| 2005 FY | - CAD | -48.93% |
| 2005 Q2 | -124.2 Thousand CAD | 6.6% |
| 2004 Q3 | -139.54 Thousand CAD | -283.11% |
| 2004 Q2 | -36.42 Thousand CAD | 81.52% |
| 2004 Q1 | -197.13 Thousand CAD | -139.29% |
| 2004 FY | - CAD | 15.47% |
| 2004 Q4 | -148.17 Thousand CAD | -6.19% |
| 2003 FY | - CAD | -572.56% |
| 2003 Q2 | -18.23 Thousand CAD | -58.5% |
| 2003 Q1 | -11.5 Thousand CAD | 31.23% |
| 2003 Q4 | -104.67 Thousand CAD | -679.76% |
| 2003 Q3 | -10.56 Thousand CAD | 42.07% |
| 2002 FY | - CAD | 23.5% |
| 2002 Q4 | -16.73 Thousand CAD | -134.51% |
| 2002 Q3 | -7135.00 CAD | 0.0% |
| 2001 FY | - CAD | -449.26% |
| 2000 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Telo Genomics Corp. | -2.66 Million CAD | 89.691% |